Published in Future Microbiol on November 18, 2016
Pathogen recognition and innate immunity. Cell (2006) 44.14
RNA interference. Nature (2002) 22.28
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol (2012) 14.55
Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med (2004) 10.91
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Plasmacytoid dendritic cells in immunity. Nat Immunol (2004) 9.11
Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol (2005) 9.00
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol (1984) 6.90
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology (2006) 6.67
Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol (2008) 6.17
Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science (2014) 5.47
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 5.37
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife (2012) 5.18
IL-21 is required to control chronic viral infection. Science (2009) 4.80
A vital role for interleukin-21 in the control of a chronic viral infection. Science (2009) 4.55
Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet (2015) 4.37
Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A (1996) 4.02
IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science (2009) 3.90
IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell (2011) 3.61
IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest (2011) 3.59
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med (1995) 3.54
The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol (2005) 3.51
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A (2004) 3.16
Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol (2003) 3.15
Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol (2005) 2.94
Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science (2003) 2.84
Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol (2000) 2.65
Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol (2011) 2.25
Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res (2007) 2.14
GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology (2013) 2.14
Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol (2005) 2.13
Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology (2004) 2.09
Clinical relevance of hepatitis B viral mutations. Hepatology (2000) 2.03
Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology (2010) 2.02
The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol (2011) 2.02
A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Hum Mol Genet (2011) 1.96
IL-7 receptor signaling is necessary for stage transition in adult B cell development through up-regulation of EBF. J Exp Med (2005) 1.94
Toll-like receptor signaling in the liver. Gastroenterology (2006) 1.94
Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology (2009) 1.88
HLA and hepatitis B infection. Lancet (1994) 1.85
Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol (2007) 1.85
IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest (2012) 1.81
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology (2009) 1.76
Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology (2001) 1.75
High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol (2011) 1.74
A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci U S A (2005) 1.72
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol (2008) 1.70
Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis. Gastroenterology (2015) 1.68
Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol (2005) 1.68
Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development. Hepatology (2012) 1.66
Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther (2010) 1.61
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology (2004) 1.59
Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology (2003) 1.59
Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology (2009) 1.59
New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol (2005) 1.57
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology (2008) 1.56
Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology (2002) 1.53
Involvement of host cellular multivesicular body functions in hepatitis B virus budding. Proc Natl Acad Sci U S A (2007) 1.49
Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology (2013) 1.45
Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One (2012) 1.44
Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc Natl Acad Sci U S A (2006) 1.41
BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. J Mol Recognit (2006) 1.41
Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology (2007) 1.38
Human clinical trials of plasmid DNA vaccines. Adv Genet (2005) 1.35
Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology (2011) 1.35
Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog (2010) 1.33
Alpha-glucosidase inhibitors as potential broad based anti-viral agents. FEBS Lett (1998) 1.32
Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother (2012) 1.31
Evaluation of genetic susceptibility loci for chronic hepatitis B in Chinese: two independent case-control studies. PLoS One (2011) 1.29
The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol (2012) 1.29
Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology (2005) 1.28
Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS One (2011) 1.27
A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrob Agents Chemother (2007) 1.27
Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut (2007) 1.26
Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther (2006) 1.25
Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends Immunol (2010) 1.25
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol (2014) 1.25
Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology (2012) 1.25
Mutations of the surface protein of hepatitis B virus. Antiviral Res (2003) 1.24
Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J Virol (2009) 1.23
Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology (2003) 1.22
Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators. ACS Chem Biol (2010) 1.21
Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int (2011) 1.21
The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res (2007) 1.21
Understanding the host genetics of chronic hepatitis B and C. Semin Liver Dis (2011) 1.20
A common HLA-DPA1 variant is a major determinant of hepatitis B virus clearance in Han Chinese. J Infect Dis (2011) 1.17
Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog (2014) 1.16
Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog (2013) 1.16
Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther (2010) 1.15
A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One (2008) 1.14
Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol (2008) 1.14
Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. J Hepatol (2014) 1.13